Mechanism of action<unk>  is an interleukin-5 antagonist monoclonal antibody. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Eosinophils play a role in the mediation of inflammation in the airways. Eosinophilic asthma is a phenotype of asthma that is characterized by the higher than normal presence of eosinophils in the lung and sputum. It has been shown that the numbers of eosinophils in the blood and bronchial fluid can correlate with asthma severity.<unk>  binds to IL-5 with a dissociation constant of 81 pM and inhibiting IL-5 signaling, which reduces the production and survival of eosinophils. However, the mechanism of<unk>  action in asthma has not been definitively established. Pharmacodynamics Reductions in blood eosinophil counts were observed following the first dose of<unk>  and maintained through 52 weeks of treatment. In phase III clinical trials, mean eosinophil counts were 696 cells/µL (n=245) and 624 cells/µL (n=244) at baseline. Following 52 weeks of<unk>  treatment, eosinophil cells were counted and were reported to be 55 cells/µL (92% reduction, n=212) and 496 cells/µL (21% reduction, n=212) for the<unk>  and placebo treatment groups, respectively. Furthermore, eosinophil count returned towards baseline in those<unk> -treated patients who completed a follow-up assessment (n=35, 480 cells/µL), approximately 120 days after the last dose of<unk> . Therefore, reductions of blood eosinophils were related to<unk>  serum levels. Pharmacokinetics The pharmacokinetic characteristics of<unk>  are similar across the children and adults. Peak serum concentrations are observed at the end of infusion and declines in a biphasic manner. The mean observed accumulation ratio of<unk>  following multiple doses of administration ranged from 1.5 to 1.9-fold.<unk>  has a volume of distribution of approximately 5 L, clearance of approximately 7 mL/hour, and a half-life of about 24 days.<unk>  is degraded by enzymatic proteolysis into small peptides and amino acids, as are other monoclonal antibodies.
Reslizumab
Brolucizumab
Inebilizumab
Crizanlizumab
Tocilizumab
Risankizumab
Natalizumab
Ravulizumab